RxDoctor Payments Data

Robert Hallivis, DPM

Foot & Ankle Surgery · Fairfax, VANPI 1215938006

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 40.7% of the total. 2025 is the largest year on record at $9,045, 6.8 times the $1,323 reported in 2019.

$20,516in general payments, 2019–2025

Across 149 payments — averaging $137.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$8K
  • Arthrex$8K
  • Stryker$1K
  • Smith+Nephew$806
  • Arteriocyte Medical Systems, Inc.$243
  • Organogenesis Inc.$203
  • plus $2K from 28 others

What the payments were for

  • Consulting fees$7,57237%
  • Speaking & faculty fees$7,50037%
  • Travel & lodging$9425%
  • Food & beverage$4,50222%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,516 in reported general payments places this provider in the 85th percentile of 260 foot & ankle surgery providers in Virginia.

See all foot & ankle surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$230,409
Medicare patients
505
Services billed
2,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole44$43,545
Tavaborole12$4,460
Fluocinonide17$842
Ciclopirox17$539
Mupirocin54$511
CiclopiroxCiclopirox Olamine26$312
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$136
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$117
Cefadroxil23$113
Doxycycline Hyclate13$90
Methylprednisolone18$82
Meloxicam11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$162$43,54544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 260 foot & ankle surgery providers in Virginia.

Other foot & ankle surgery in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →